Lipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint

Lipocine Inc LPCN shares are trading higher by 22 cents (4.4 percent) at $4.24 in Tuesday's session.

After Monday's close, the company announced that LPCN 1021 had met its primary endpoint. The drug "is a novel oral product candidate of Testosterone (T) containing Testosterone Undecanoate (TU) that is designed to help restore normal T levels in males for conditions associated with a deficiency or absence of endogenous testosterone."

After a much higher open, Lipocine immediately peaked at $5.14 and reversed course as profit-takes swarmed the stock. That marks the first time it has been over $5.00 since October 12, 2016, when it peaked at $5.42, but weakened to end that session at $4.60.

At this time, the retreat is attempting to find support near the top of Monday's range ($4.12) as $4.16 stands as the current low for the session.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!